Age-related macular degeneration (AMD) affects the macula — the retinal area responsible for sharp central detail. Early AMD may cause no symptoms. Later disease can make text blurry, faces harder to recognize, straight lines appear wavy, and the center of vision become distorted or missing. Modern retinal care can slow many forms of AMD, but the correct treatment depends on the exact type and stage.
| Warning Sign | Possible Concern | Action |
|---|---|---|
| Straight lines suddenly look wavy | New macular distortion / possible wet AMD | Prompt retinal assessment. |
| New central dark/blank spot | Macular damage, bleeding or fluid | Urgent eye/retina evaluation. |
| Sudden central vision loss | Wet AMD, vascular or retinal emergency | Urgent ophthalmic care. |
| Flashes, many floaters or curtain/shadow | Retinal tear/detachment rather than typical AMD | Emergency retinal assessment. |
| Severe eye pain + vision loss | Not typical AMD; other eye emergency possible | Emergency care. |
The retina lines the back of the eye and converts light into signals that travel to the brain. At its center is the macula, a specialized area responsible for detailed straight-ahead vision. When AMD damages the macula, central tasks become difficult even when peripheral vision remains useful.
| Visual Task | Why the Macula Matters |
|---|---|
| Reading | Fine central detail is needed to identify letters and words. |
| Recognizing faces | Facial detail depends heavily on central vision. |
| Driving | Road signs, lane detail and hazards require good central acuity. |
| Cooking / sewing / repairs | Small objects and precise hand-eye tasks use the macula. |
| Peripheral navigation | Side vision comes from more peripheral retina and can remain useful even with advanced AMD. |
| Feature | Dry AMD | Wet / Neovascular AMD |
|---|---|---|
| Main process | Age-related macular changes, drusen and progressive retinal/RPE degeneration | Abnormal blood vessels grow and leak fluid or blood |
| Frequency | More common | Less common |
| Typical speed | Often slower over years | Can worsen rapidly |
| Late form | Geographic atrophy | Neovascular/exudative AMD |
| Treatment | Stage-specific monitoring, AREDS2 where indicated, risk reduction; complement-inhibitor injections for geographic atrophy in some countries/patients | Usually anti-VEGF injections; selected additional retinal therapies |
Dry AMD can convert to wet AMD. New distortion, a central dark spot or rapidly worsening vision should never be dismissed as normal aging.
| Stage | What May Be Happening | Symptoms | Typical Priority |
|---|---|---|---|
| Early AMD | Small/medium drusen and early retinal changes | Often none | Monitoring and risk-factor control |
| Intermediate AMD | Larger drusen / pigmentary changes | May have mild central blur or low-light difficulty | Closer monitoring; AREDS2 may be appropriate |
| Late dry AMD | Geographic atrophy | Expanding central/near-central blind areas | Retina specialist; consider eligible GA therapies and low vision |
| Late wet AMD | Leaking/bleeding abnormal vessels | Distortion, rapid blur, central scotoma | Prompt anti-VEGF retinal care |
| Symptom | Real-Life Example | Clinical Message |
|---|---|---|
| Central blur | Face looks blurred while surrounding room is visible | Macular function may be affected |
| Metamorphopsia | Door frame or grid line looks bent | New distortion needs prompt assessment |
| Central blind spot | A letter/face disappears when looked at directly | Advanced macular damage possible |
| Low contrast | Grey-on-grey objects are difficult to separate | Common in macular disease and cataract |
| More light needed | Reading is easier under bright task lighting | Can occur with AMD, cataract and aging |
| Reduced color vividness | Colors appear duller | May occur in advanced disease |
| Risk Factor | Modifiable? | Practical Response |
|---|---|---|
| Age | No | Risk-based regular dilated examinations |
| Family history / genetics | No | Tell your eye doctor; monitor appropriately |
| Smoking | Yes | Stop smoking; seek cessation support if needed |
| Cardiovascular health | Partly | Manage blood pressure, exercise and general vascular health with your doctor |
| Diet / physical activity | Partly | Balanced nutrient-rich diet and regular activity |
| Existing AMD in one eye | No | Close fellow-eye monitoring and home symptom awareness |
The older version of this article overstated the evidence by presenting blue light and sunlight as active causes of AMD. A more accurate 2026 message is that age, smoking and family history have clearer established associations, while ordinary screen blue-light exposure has not been proven to cause AMD.
| Claim | Evidence-Based Position |
|---|---|
| "Phone blue light causes AMD." | Not established. Screen use is more relevant to digital eye strain, blinking and sleep habits than AMD prevention. |
| "Blue-light glasses prevent macular degeneration." | Not proven. Choose computer lenses for visual comfort or prescription needs, not as an AMD cure. |
| "UV-protective sunglasses are useless." | False. UV protection remains sensible for general eye protection outdoors, even though it should not be marketed as a guaranteed AMD-prevention treatment. |
| Test | What It Shows | Typical Role |
|---|---|---|
| Visual acuity | Central reading/detail ability | Measures functional vision |
| Dilated retinal examination | Drusen, pigment changes, bleeding, fluid or atrophy | Core diagnostic examination |
| OCT | Cross-sectional retinal layers, fluid, atrophy and structural change | Diagnosis and treatment monitoring |
| Amsler grid | Subjective distortion or missing areas | Home monitoring and symptom documentation |
| OCT angiography / fluorescein angiography | Abnormal retinal/choroidal vessels and leakage patterns | Selected suspected wet AMD cases |
Vision Concern's current Comprehensive Eye Examination can identify reduced acuity, refractive blur and visible eye-health findings. Suspected macular disease may require dilated retinal examination, OCT or other specialist imaging beyond a routine optical visit.
| Step | How to Check |
|---|---|
| 1 | Wear your normal reading correction if prescribed. |
| 2 | Use good, even lighting and hold the grid at your usual reading distance. |
| 3 | Cover one eye without pressing on it. |
| 4 | Look at the center dot and keep your gaze there. |
| 5 | Notice whether lines look newly wavy, missing, distorted or blurred. |
| 6 | Repeat with the other eye and report new changes promptly. |
A normal grid does not rule out early AMD. It is a monitoring aid for people at risk or already diagnosed, not a replacement for dilated retinal examination.
AREDS2 is not a general "eye vitamin" and it does not prevent AMD from starting. The National Eye Institute found that AREDS/AREDS2 formulations reduce progression from intermediate to advanced AMD in appropriate patients.
| AREDS2 Ingredient | NEI Formula Amount |
|---|---|
| Vitamin C | 500 mg |
| Vitamin E | 400 IU |
| Zinc | 80 mg |
| Copper | 2 mg |
| Lutein | 10 mg |
| Zeaxanthin | 2 mg |
| Beta-carotene | Not included in AREDS2 |
| May Benefit | Not a Reason to Self-Start |
|---|---|
| Intermediate AMD in one or both eyes | Being over age 50 without AMD |
| Certain people with late AMD in one eye | Having cataract alone |
| Patients whose retina specialist confirms the appropriate stage | Wanting a general "vision booster" |
| Current/former smokers should use AREDS2 rather than beta-carotene AREDS if indicated | Taking another high-dose supplement without checking interactions |
High-dose supplements can interact with health conditions and medicines. Confirm the AMD stage and discuss the formula with the treating doctor before starting.
Wet AMD is driven by abnormal blood-vessel growth and leakage. Anti-VEGF medicines are injected into the eye by a retina specialist to suppress that pathway, reduce leakage and protect central vision.
| Treatment Goal | What Anti-VEGF Can Do | What It Cannot Promise |
|---|---|---|
| Reduce leakage | Dry retinal fluid and reduce active neovascular leakage | Guaranteed permanent cure |
| Protect vision | Many patients can stabilize; some improve | Restore every cell already damaged |
| Control disease over time | Repeated treatment can suppress recurrence | One injection always being enough |
Injection interval is individualized. The retina specialist may use fixed dosing, treat-and-extend or another evidence-based schedule depending on OCT findings and disease activity.
The older 2024 article said there was no treatment for late dry AMD and then incorrectly described newer medicines as "pills." The 2026 update is more precise: in the United States, SYFOVRE (pegcetacoplan) and IZERVAY (avacincaptad pegol) are FDA-approved intravitreal injections for geographic atrophy secondary to AMD.
| Drug | Mechanism | Goal | Important Point |
|---|---|---|---|
| SYFOVRE (pegcetacoplan) | Complement C3 inhibitor | Slow geographic-atrophy lesion growth | Intravitreal injection; has important retinal/inflammatory risks |
| IZERVAY (avacincaptad pegol) | Complement C5 inhibitor | Slow geographic-atrophy lesion growth | Intravitreal injection; does not restore already-lost retinal tissue |
Availability, approval and cost vary by country. Patients in Nepal should discuss eligibility and current access with a retina specialist rather than ordering or seeking these medicines independently.
| AMD Stage | Typical Management | Main Goal |
|---|---|---|
| Early dry AMD | Regular examination, smoking cessation, cardiovascular/lifestyle care | Monitor progression |
| Intermediate AMD | Monitoring + AREDS2 when indicated | Reduce progression risk |
| Wet AMD | Anti-VEGF retinal injections; selected additional therapy | Control leakage and protect vision |
| Geographic atrophy | Low-vision support; selected eligible patients may consider complement inhibitors where available | Slow lesion growth and maximize function |
| Any stage + refractive error/cataract | Optimize glasses and address other treatable visual causes | Preserve every possible line of useful vision |
| Feature | AMD | Cataract |
|---|---|---|
| Affected structure | Macula / retina | Natural lens |
| Typical blur | Central distortion, missing detail | General haze, glare, halos, faded vision |
| Straight lines wavy? | Can occur | Not a classic cataract feature |
| Definitive treatment | Depends on AMD type/stage | Cataract surgery replaces cloudy lens |
| Can cataract surgery cure it? | No | Cataract itself is removed surgically |
| Condition | Main Structure | Classic Pattern |
|---|---|---|
| AMD | Macula / retina | Central blur/distortion, side vision often preserved |
| Glaucoma | Optic nerve | Peripheral field loss often before central vision |
| Cataract | Natural lens | General haze, glare and contrast reduction |
| Habit | Why It Matters |
|---|---|
| Stop smoking | One of the strongest modifiable AMD risk actions. |
| Balanced diet | Supports general cardiovascular and retinal health; not a substitute for stage-specific treatment. |
| Exercise / vascular health | Supports overall health and modifiable cardiovascular risk. |
| Regular eye examinations | Early AMD can be asymptomatic. |
| Home symptom monitoring if advised | Helps identify new distortion between visits. |
| UV-protective outdoor eyewear | Sensible general ocular protection without claiming it cures/prevents AMD. |
| Food Pattern | Examples | AMD Message |
|---|---|---|
| Dark leafy greens | Spinach, kale, mustard greens | Sources of lutein/zeaxanthin; part of a healthy diet |
| Colorful vegetables | Peppers, broccoli, corn | Supports varied nutrient intake |
| Fish | Salmon, sardines and other fish | Healthy dietary pattern; omega-3 supplements did not add AREDS2 benefit |
| Whole foods | Whole grains, legumes, nuts, fruit | Supports cardiovascular/metabolic health |
AMD damage cannot be sharpened away with stronger lenses, but refractive error, cataract and poor contrast can coexist. The practical goal is to optimize every correctable component of vision.
| Optical Tool | How It Can Help | Limitation |
|---|---|---|
| Updated prescription glasses | Remove additional myopic, hyperopic or astigmatic blur | Cannot repair retinal tissue |
| High-add reading correction | Magnifies text for selected low-vision tasks | Working distance becomes closer |
| Anti-reflective coating | Can improve spectacle clarity and reduce reflections | Not an AMD treatment |
| Tint / contrast filter | May improve comfort/contrast for some people | Benefit varies; no universal best color |
When a retina specialist says the prescription is stable, Vision Concern can provide Prescription Glasses and genuine ZEISS Prescription Lenses to optimize remaining optical clarity.
| Low-Vision Strategy | Useful For |
|---|---|
| Hand / stand magnifier | Short labels, medicine bottles, prices |
| Electronic video magnifier | Extended reading with adjustable magnification and contrast |
| Large text / accessibility settings | Phones, tablets and computers |
| Task lighting | Reading, cooking, hobby work |
| Contrast marking | Steps, switches, kitchen controls, household safety |
| Eccentric-viewing training | Learning to use healthier peripheral retinal areas when central scotoma is present |
| Driving Concern | Why It Matters |
|---|---|
| Road signs blur centrally | Central acuity may no longer meet safe/legal requirements. |
| Night glare / poor low-light detail | Contrast loss and coexisting cataract can worsen night performance. |
| Central blind spot | Can hide pedestrians, vehicles or road hazards. |
| Wavy lines / distortion | May signal active macular change and unsafe visual interpretation. |
Do not rely on a special lens coating to make unsafe central vision safe for driving. Driving fitness depends on visual acuity, visual field, contrast, disease stability and local legal requirements.
| Action | Reason |
|---|---|
| Check each eye separately | The better eye can mask deterioration in the other. |
| Follow retina-specialist monitoring schedule | Risk can differ greatly between eyes. |
| Use Amsler monitoring if advised | New distortion may be detected sooner. |
| Do not smoke | Reduces an important modifiable risk. |
| Use AREDS2 only if the stage qualifies | Stage-specific benefit, not universal prevention. |
Older adults may have AMD together with cataract, glaucoma, dry eye, diabetes or refractive error. A treatment plan should separate what is retinal, what is optical, and what may be surgically correctable.
| Coexisting Problem | Why It Matters |
|---|---|
| Cataract | Can add haze/glare on top of macular blur. |
| Glaucoma | Can reduce peripheral field while AMD reduces central detail. |
| Dry eye | Adds fluctuating optical blur that may be treatable. |
| Refractive error | Correcting it helps maximize useful remaining vision. |
| Diabetic retinal disease | Requires medical retinal monitoring separate from AMD. |
Travelers may first notice central blur while reading maps, reviewing a phone screen, recognizing faces or checking trekking details. Vision Concern's current Eye Care for Tourists & Expats service provides English-speaking eye examinations and can recommend urgent ophthalmology or retina referral if macular disease is suspected.
| Visitor Situation | Best Next Step |
|---|---|
| New wavy lines / central distortion | Prompt retina-capable assessment. |
| Gradual central blur | Comprehensive examination + retinal referral if indicated. |
| Lost glasses + known AMD | Replace correctable refractive component without assuming glasses treat AMD. |
| Already receiving injections abroad | Carry recent OCT, injection dates, drug name and treating-retina notes; arrange retina specialist continuity. |
| Vision Concern Can Help With | Requires Retina / Ophthalmology Care |
|---|---|
| Visual-acuity testing and refraction | Definitive diagnosis/staging of suspected AMD with specialized retinal examination/imaging |
| Comprehensive eye-health screening | Anti-VEGF retinal injections |
| Optimizing prescription glasses | SYFOVRE / IZERVAY injections |
| Recognizing red flags and arranging referral | Retinal laser, photodynamic therapy or retinal surgery when indicated |
| Supporting tourists/expats with records and optical needs | Medical management of active neovascular AMD |
| Myth | Reality |
|---|---|
| "AMD always causes total blindness." | AMD primarily affects central vision; peripheral vision often remains. |
| "Blue-light glasses prevent AMD." | Not proven. Screen-comfort lenses should not be sold as AMD prevention. |
| "AREDS2 prevents AMD in healthy eyes." | NEI states AREDS/AREDS2 does not prevent AMD onset. |
| "AREDS2 contains beta-carotene." | Current AREDS2 uses lutein and zeaxanthin; beta-carotene is omitted. |
| "SYFOVRE and IZERVAY are pills." | They are intravitreal injections for geographic atrophy. |
| "Cataract surgery cures AMD." | Cataract surgery treats the lens, not the macula. |
| "A normal vision chart means no AMD." | Early AMD can be asymptomatic; dilated retinal examination is important. |
| If This Describes You... | Next Action |
|---|---|
| Age 55+ with no symptoms | Maintain regular comprehensive/dilated eye examinations according to risk. |
| Family history of AMD | Tell your eye doctor and follow a risk-based exam schedule. |
| Intermediate AMD | Ask whether AREDS2 is appropriate and monitor for new distortion. |
| New wavy lines / central spot | Prompt retina assessment for possible wet AMD. |
| Geographic atrophy | Discuss low-vision support and current eligible retinal treatments with a retina specialist. |
| Known AMD + outdated glasses | Optimize refractive correction while continuing retinal follow-up. |
Vision, refraction and eye-health screening to identify when retinal referral is needed.
Suspected AMD, wet macular change or significant central vision loss can be referred for specialist retinal evaluation.
Updated prescription glasses can optimize the correctable component of remaining vision.
A current Vision Concern trust credential.
International professional affiliation.
Professional optical guidance for genuine ZEISS prescription lenses.
International patient-service recognition received in 2018.
Serving local and international patients across Kathmandu.
| Branch | TripAdvisor | WhatClinic | |
|---|---|---|---|
| Boudha-Tushal | Google Reviews | TripAdvisor | WhatClinic |
| Lazimpat | Google Reviews | TripAdvisor | WhatClinic |
| Makalbari | Google Reviews | TripAdvisor | WhatClinic |
Age-related macular degeneration, or AMD, is a retinal disease that damages the macula, the central part of the retina responsible for sharp straight-ahead vision used for reading, recognizing faces and seeing fine detail.
AMD primarily damages central vision. Peripheral or side vision is often preserved, so it does not usually cause complete total blindness, although advanced central vision loss can seriously affect independence.
The two broad categories are dry AMD and wet, or neovascular, AMD. Dry AMD is more common and often progresses slowly. Wet AMD is less common but can cause faster central vision loss because abnormal blood vessels leak or bleed.
Geographic atrophy is an advanced form of dry AMD in which areas of retinal cells progressively degenerate, causing expanding areas of central or near-central vision loss.
Wet AMD, also called neovascular AMD, occurs when abnormal blood vessels grow beneath or within the retina and leak fluid or blood, damaging the macula.
Early AMD often causes no symptoms. This is why dilated eye examinations are important for people at risk.
Macular swelling or structural change can distort the retinal image, making straight lines such as door frames, tiles or text appear wavy or bent. New distortion needs prompt retinal assessment.
Yes. Advanced AMD can create a central scotoma, or missing/blurred patch, while side vision may remain.
Yes. Some people with advanced AMD notice reduced contrast and colors that appear less bright or vivid.
AMD can make low-light tasks more difficult, especially in intermediate or advanced stages, although night-vision problems can also be caused by cataract and other eye conditions.
Risk increases with age. The National Eye Institute notes that people age 55 and older are more likely to develop AMD.
Yes. A family history of AMD increases risk, reflecting inherited genetic susceptibility as well as shared environmental factors.
Yes. Smoking is one of the strongest modifiable risk factors for AMD and is associated with higher risk of developing and progressing the disease.
Typical everyday screen exposure has not been proven to cause AMD. It is more accurate to address screen comfort separately from AMD risk rather than claim that blue-light glasses prevent macular degeneration.
Research on sunlight exposure and AMD risk is less definitive than for smoking and age. Good UV-protective sunglasses are sensible for general ocular sun protection, but they should not be advertised as a proven AMD treatment.
No diet guarantees prevention. A balanced diet rich in vegetables, fruits, whole foods and fish can support general health, while specific AREDS2 supplements are used only for particular AMD stages under professional guidance.
AREDS2 is a specific high-dose combination of vitamin C, vitamin E, zinc, copper, lutein and zeaxanthin studied for people with intermediate or certain late AMD. It is not an ordinary multivitamin.
No. The current AREDS2 formula uses lutein and zeaxanthin instead of beta-carotene. The older AREDS formula contained beta-carotene.
NEI research found a higher incidence of lung cancer among former smokers who received beta-carotene-containing AREDS formulations. Current and former smokers are advised to use the AREDS2 formulation rather than the older beta-carotene formula.
No. NEI states that AREDS/AREDS2 supplements do not prevent AMD onset. They are used to reduce progression risk in appropriate stages.
People with intermediate AMD in one or both eyes, or certain people with late AMD in one eye, may benefit. An eye-care professional should confirm the stage before recommending the formula.
No. High-dose AREDS2 supplements are not recommended simply because of age. They are intended for specific AMD stages and can interact with health conditions or medicines.
Glasses cannot reverse retinal damage from AMD, but an accurate prescription, magnification, lighting and low-vision aids can help make the best use of remaining vision.
No. Cataract surgery removes a cloudy natural lens, while AMD affects the retina. Cataract surgery may improve vision limited by cataract, but it does not treat macular degeneration.
Diagnosis may include visual acuity, dilated retinal examination, optical coherence tomography, Amsler-grid testing and, when indicated, retinal imaging such as OCT angiography or fluorescein angiography.
An Amsler grid is a square grid used to notice new central distortion or missing areas. It can help people with diagnosed AMD monitor vision between visits, but it does not replace retinal examinations.
Wear your usual near correction, cover one eye, focus on the central dot at the recommended reading distance and note any new wavy, missing or distorted lines. Test each eye separately and report new changes promptly.
No. Early AMD may have no symptoms and a normal home grid. Dilated examination and retinal imaging are more sensitive for diagnosis and monitoring.
Wet AMD is commonly treated with intravitreal anti-VEGF medicines that reduce abnormal blood-vessel growth and leakage. The retina specialist chooses the drug and injection schedule.
Anti-VEGF medicines are injected into the eye by a trained ophthalmologist to block vascular endothelial growth factor, a key driver of abnormal blood-vessel growth in wet AMD.
They can stabilize vision and sometimes improve it, especially when wet AMD is treated promptly, but results vary and treatment does not guarantee restoration of all lost vision.
Schedules vary by drug, disease activity and retina-specialist protocol. Some patients receive loading doses followed by treat-and-extend or individualized intervals.
Yes. In the United States, complement inhibitors such as pegcetacoplan (SYFOVRE) and avacincaptad pegol (IZERVAY) are FDA-approved for geographic atrophy secondary to AMD. They are intravitreal injections that slow lesion growth; they do not restore already-lost retinal tissue. Availability differs by country.
No. SYFOVRE is an intravitreal injection, not a pill.
No. IZERVAY is an intravitreal injection used for geographic atrophy secondary to AMD.
This article does not claim that Vision Concern administers anti-VEGF, SYFOVRE, IZERVAY or other retinal injections. Vision Concern can provide a comprehensive eye examination and arrange ophthalmology or retina referral when macular disease is suspected.
There is currently no single cure that restores the macula to normal. Treatment aims to slow progression, control wet AMD activity, reduce geographic-atrophy progression where appropriate and maximize remaining vision.
Low-vision rehabilitation combines magnification, lighting, contrast strategies, electronic devices, task modification and orientation techniques to help people use remaining vision more effectively.
Yes. Optical magnifiers, electronic video magnifiers, larger text and high-contrast devices can improve reading and detailed tasks for many people with central vision loss.
Yes. AMD and refractive error can coexist. Correcting avoidable optical blur is worthwhile even when glasses cannot repair retinal damage.
Yes. AMD can differ substantially between eyes. Each eye should be tested separately, and people with advanced disease in one eye need careful monitoring of the fellow eye.
Dry AMD often progresses gradually, but conversion to wet AMD can cause sudden or rapid distortion, blur or a new central dark spot. New changes should be assessed promptly.
Seek prompt eye or retina assessment. New metamorphopsia can be a sign of wet AMD or another macular disorder.
Yes. Vision Concern provides English-speaking comprehensive eye examinations for tourists and expats and can recommend ophthalmology or retina referral if macular disease is suspected.
Message Vision Concern on WhatsApp at +977 9841466716. Mention your age, whether the change is sudden or gradual, one or both eyes, whether straight lines look distorted, and any previous retinal diagnosis or scans.
If straight lines look wavy, faces are becoming harder to recognize or a new central spot appears, arrange prompt professional assessment. Vision Concern can provide the initial eye examination and guide referral to retinal/ophthalmic care when AMD is suspected.
Boudha: 01-4562303 | Lazimpat: 01-4543117 | Makalbari: 01-5134042
WhatsApp / Viber: +977 9841466716
Current Website Hours: 08:00 AM - 08:30 PM every day, including public holidays.
Book on WhatsAppCall Vision ConcernMedical disclaimer: This article is educational and does not replace a dilated retinal examination, OCT, retina-specialist diagnosis or individualized treatment. Sudden central vision loss, new marked distortion, a new dark central spot, flashes with many new floaters, a curtain/shadow, severe eye pain, significant injury or neurological symptoms require prompt medical/ophthalmic assessment.
Vision Concern offers:
Yes.
If your frame is in good condition, we can replace only the prescription lenses with options including:
Many international insurance providers may reimburse eye examinations or prescription eyewear depending on the policy. We recommend checking with your insurer before your visit, and we can provide invoices and supporting documentation when required.